4D Advisors Bows Out of Masimo: A Tragi-Comedy in Three Acts 🎭

by

On the fourteenth day of November, 2025, as the financial world held its breath, 4D Advisors, LLC performed a maneuver as swift as Harpagon clutching his purse-divesting its entire stake in Masimo (MASI 0.92%) to the tune of $7.57 million. Thus unfolds our tale, where hubris and hubbub collide in the grand theater of modern capitalism.

Act I: The Exit

As recorded in the sacred scrolls of the Securities and Exchange Commission, our protagonists at 4D Advisors concluded their dalliance with Masimo by casting off 45,000 shares into the void. This liquidation, valued at approximately $7,569,900, was executed with the precision of a surgeon’s scalpel-or perhaps a fleeing actor’s haste from a collapsing stage set.

Act II: The Aftermath

  • Masimo’s absence now echoes through 4D’s 13F portfolio like a forgotten chorus line, its 4.0699% former prominence reduced to mathematical vapor
  • The fund’s new pantheon of holdings includes NASDAQ: APEI, a literary critic’s dream at 5.5685% of AUM, and NYSE: TPB, a tobacco concern that smokes with vigor
  • Masimo’s shares, priced at $151.12 on the day of reckoning, have declined more steeply than a Parisian opera house’s budget
  • The stock’s 19.04 percentage point underperformance against the S&P 500 suggests even the market’s fickle goddess has turned her back

Act III: The Players

Measure Value
Revenue (TTM) $1.72 billion, a sum sufficient to fund a minor principality
Net Income (TTM) ($569.40 million), a loss so grand it would make Tartuffe blush
Market Cap $8.16 billion, a figure that winks at its $10 billion aspirations
Price $151.12, a number as precise as a watchmaker’s pocket watch

Company Portrait

  • Masimo, that most earnest of tragedians, performs its noninvasive monitoring technologies for audiences in hospitals and beyond
  • Its revenue streams flow from both direct sales and OEM partnerships-a double helix of commerce
  • Hospitals, veterinarians, and even the occasional hypochondriac consumer constitute its loyal patrons

Let us not forget: Masimo fancies itself a global leader in patient monitoring, wielding signal extraction technology like Excalibur against the dragon of clinical uncertainty. Yet its consumer electronics ventures-ah, quelle farce!-have proven as successful as a silk umbrella in a monsoon.

Fool’s Perspective

This divestiture marks Masimo’s exit from 4D’s top tier, leaving nary a medical device maker among its principal holdings. The company’s smartwatch ambitions, one might say, have tripped over their own shoelaces-though the core healthcare business marches on with the vigor of a freshly pomaded courtier.

Management’s forecast of 8.5-10% revenue growth, delivered with the solemnity of a state funeral, assumes favorable exchange rates-a hope as fragile as a Venetian glass. Meanwhile, the sale of Sound United to Harman and expanded Philips (PHG 1.04%) partnership suggest a return to roots, albeit with pockets slightly heavier and forehead slightly redder.

A Lexicon for the Perplexed Investor

13F reportable assets under management: The quarterly confessional where funds bare their financial souls to the SEC

Full exit: The financial equivalent of fleeing a burning theater

OEM partnerships: Corporate marriages of convenience, where brands don borrowed finery

Capnography: The art of measuring breath’s carbonaceous sighs-vital for both patients and dramatists requiring dramatic pauses

Read More

2025-11-16 20:14